Serial changes in the expression of breast cancer-related proteins in response to neoadjuvant chemotherapy
B Y S Chuah, T Putti, M Salto-Tellez, A Charlton, P Iau, S A Buhari, C I Wong, S H Tan, A L A Wong, C W Chan, B C Goh, S C Lee, B Y S Chuah, T Putti, M Salto-Tellez, A Charlton, P Iau, S A Buhari, C I Wong, S H Tan, A L A Wong, C W Chan, B C Goh, S C Lee
Abstract
Background: Tumour expression of cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), erythroblastic leukaemia viral oncogene homologue-2 (ErbB2), Ki-67 and p53 in breast cancer are associated with poorer outcomes. We investigated in vivo changes of these proteins with neoadjuvant chemotherapy.
Patients and methods: Four core biopsies were taken from 100 breast cancer patients at baseline, during and upon completion of neoadjuvant chemotherapy. Immunohistochemical expression of these proteins were evaluated and correlated with clinicopathological features, clinical response and progression-free survival (PFS).
Results: There was a statistically significant change from positivity to negativity in COX-2 expression with chemotherapy (P = 0.002), predominantly in clinical responders (P = 0.002). COX-2-positive tumours that remained positive had shorter PFS than those that turned negative. Estrogen receptor (ER)+ and COX-2+ tumours at baseline that remained COX-2+ fared worse than those that became COX-2 negative (PFS 27 versus 52 months, P = 0.002). No significant changes in IHC expression were observed for ER, progesterone receptor, ErbB2, EGFR, p53 or Ki67.
Conclusions: Chemotherapy induced change in COX-2 expression from positivity to negativity predominantly among clinical responders and is associated with longer PFS. Interaction between COX-2 and ER was observed, suggesting that some hormone receptor-positive patients may benefit from combining COX-2 inhibition with hormonal therapy.
Trial registration: ClinicalTrials.gov NCT00212082.
Source: PubMed